| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-02-05 | Metrion Biosciences (UK) | £200 000 | grant | Innovate UK Biomedical Catalyst Feasibility Award scheme (UK) | Autoimmune diseases - Neurodegenerative diseases | Grant |
| 2018-02-02 | Viking Therapeutics (USA - PA) | $55 million | private placement | Endocrinological diseases - Metabolic diseases | Private placement | |
| 2018-02-02 | Medivir (Sweden) | 155 million SEK (€ 15.75 million) | Infectious diseases | Private placement | ||
| 2018-01-23 | Tmunity Therapeutics (USA - PA) | $ 100 million | series A financing round | Ping An Ventures (China) Parker Institute for Cancer Immunotherapy (USA - CA) Gilead Sciences (USA - CA) Be The Match BioTherapies University of Pennsylvania (USA - PA) Lilly Asia Ventures (China) | Cancer - Oncology - Autoimmune diseases - Infectious diseases | Series A financing round |
| 2018-01-23 | Skyhawk Therapeutics (USA - MA) | $ 8 million | financing round | Tim Disney, the Duke of Bedford, Alexandria Venture Investments (USA - MA) and other undisclosed private investors | Cancer - Oncology - Neurological diseases | Financing round |
| 2018-01-16 | Arbutus Biopharma (Canada) | US$116.4 million | private placement | Roivant Sciences (CH - USA) | Infectious diseases | Private placement |
| 2018-01-05 | Advicenne (France) | €27.8 million | IPO | Rare diseases - Genetic diseases - Pediatric diseases | IPO | |
| 2018-01-04 | Enterome Bioscience (France) | €40 million | loan | European Investment Bank (EIB) | Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology | Loan |
| 2018-01-04 | Enterome Bioscience (France) | €32 million ($38.5 million) | series D financing round | BMS (USA - NY) Principia SGR (Italy) Health For Life Capital (Seventure) (France) Lundbeckfond Venture (Denmark) Nestlé Health Science (Switzerland) Omnes Capital (France) | Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology | Series D financing round |
| 2018-01-04 | Acticor Biotech (France) | €3.9 million | financing round | Primer Capital (Russia) Anaxago (France) CapDecisif Management (France) private investors | Cerebrovascular diseases | Financing round |
| 2017-12-29 | Armo BioScience | IPO | Cancer - Oncology | IPO | ||
| 2017-12-22 | Sagetis Biotech (Spain) | undisclosed | grant | Duchenne Parent Project España (Spain) | Cancer - Oncology - Rare diseases | Grant |
| 2017-12-21 | Taris Biomedical (USA - MA) | $ 25 million | series B financing round | BMS (USA - NY) Flagship Pioneering (USA - MA) Norma Investments (UK) Polaris Partners (USA - MA) RA Capital Management (USA - MA) Yonghua Capital (China) | Cancer - Oncology | Series B financing round |
| 2017-12-20 | Orchard Therapeutics (UK) | $110 million (£85 million) | series B financing round | Baillie Gifford (UK) ORI Capital Temasek (Singapore) Cowen Healthcare Investments (USA - NY) Juda Capital, Pavilion Capital (USA - NY) RTW Investments (USA - NY) 4BIO Capital (UK) F-Prime Capital (USA -MA) UCL Technology Fund (UK) | Rare diseases - Genetic diseases | Series B financing round |
| 2017-12-18 | Mereo BioPharma (UK) | IPO | Rare diseases - Genetic diseases | IPO | ||
| 2017-12-15 | Blueprint Medicines (USA - MA) | $325.5 million | private placement | Private placement | ||
| 2017-12-15 | Univercells (Belgium) | €3 million ($3.56M) | series A financing round | Takeda Ventures, US and EU private investors | Technology - Services | Series A financing round |
| 2017-12-14 | OSE Immunotherapeutics (France) | €398,000 | grant | FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France | Cancer - Oncology | Grant |
| 2017-12-12 | NorthSea Therapeutics (The Netherlands) | € 25 million | series A financing round | Forbion Capital Partners (The Netherlands) BioGeneration Ventures (The Netherlands) Novo Seeds (Denmark) New Science Ventures (USA - NY) | Hepatic diseases - Liver diseases - Inflammatory diseases | Series A financing round |
| 2017-12-12 | bluebird bio (USA - MA) | $600 million | private placement | Rare diseases - Genetic diseases | Private placement |
